Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Urinary Bladder Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).

PET CT

Bladder cancer is the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years.

Optimal staging of lymph nodes and metastasis is crucial for treatment decision of muscle invasive bladder cancer (MIBC).

Guidelines do not recommend FDG-Positron Emission Tomography (PET) Computed Tomography (CT), but rather CT for lymph node and metastatic staging, despite its low accuracy. We performed a retrospective analysis of patients undergoing PET CT for localized MIBC in two centers, to help define the utility of PET CT in this setting.

Background:

Bladder cancer is the second most frequent genito-urinary cancer, and the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Curative treatment of muscle invasive urothelial carcinoma localized to the bladder includes cisplatin-based neoadjuvant chemotherapy, followed by radical cystectomy with lymph nodes dissection. Nonetheless, surgery indications depend on pre-operative staging regarding nodes and metastatic involvement.

Computed Tomography (CT) scan is the reference imaging study for loco-regional and metastatic staging. Lymph node involvement evaluation is based on morphologic criteria only. Its sensitivity lies between 30 and 53% and its specificity between 67 and 91%. Yet, optimal node staging is crucial for therapeutic decision.

FDG-Positron Emission Tomography (PET) CT, using both morphologic and functional criteria, could help for node staging in muscle invasive bladder cancer assessment, especially by detecting infracentimetric involved lymph nodes. Moreover, it could be useful for detecting distant metastasis.

Objective:

To evaluate the accuracy of the PET CT for lymph node staging and to determine the rate of treatment modification according to PET CT results

Methods:

Retrospective study based on the medical records of every patient undergoing a PET CT at the time of diagnosis of MIBC from 01/2005 to 12/2017 in Bordeaux (Bergonie Institute and University Hospital). PET CT could have been done before any treatment (PET 1) and/or after neo-adjuvant chemotherapy and before surgery (PET 2).

Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer

Description: Assess differences between planned management before knowing the FDG-PET CT results and treatment actually received.

Comparison of lymph nodes staging on PET CT (according to EORTC criteria) and lymph nodes staging on pathological report, according to the AJCC TNM Staging System for Bladder Cancer 8th ed., 2017.

Evaluation of the concordance rate between PET CT results (according to EORTC criteria) and CT scan results (according to RECIST 1.1) for lymph node and metastatic staging according to the AJCC TNM Staging System for Bladder Cancer 8th ed., 2017.

Comparison of PET-CT TNM staging between patients with and patients without a Pathological Complete Response

Comparison of Recurrence Free Survival for patients with and patients without a Complete Metabolic Response (according to EORTC criteria)

Institut Bergonié

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Carlo De Cecco, MD PHD

The overall goal of this project is to investigate the diagnostic performance of integrated F-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) and Dual Energy CT (DECT) imaging in determining the thoracic nodal status of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), and its impact on target volume delineation for image guided radiation therapy (IGRT) planning.

PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer

Application of Integrated PET and Dual Energy CT Imaging for Staging and Imaged Based Radiotherapy Treatment Planning in Lung Cancer

Knowledge gained during this study may potentially allow for an improvement in PET-CT accuracy for lung tumor and thoracic adenopathy detection, and for a more accurate definition of the RT target, decreasing the radiation dose delivered to normal tissue.

Siemens Corporation, Corporate Technology

Medical University of South Carolina

Immune System Diseases

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Carcinoma

Hypersensitivity

Nasopharyngeal Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT and ultrasensitive PET CT protocol 12 weeks after the end of IMRT .

A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.

ultrasensitive PET CT

Haiqiang Mai, Dr

NPC Patients receiving IMRT treatment will receive a dedicated FDG PET/CT and high-sensitivity PET/CT protocol simultaneously in the follow-up of Locally Advanced Nasopharyngeal Carcinoma. Hence we establish this prospective cohort study.

Newly-diagnosed patients with stage III or IV non-metastatic Nasopharyngeal Carcinoma (AJCC 8th) will be recruited. All subjects receiving chemoradiotherapy will undergo a baseline integrated \[18F\]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) scan or traditional follow-up examination before the start of chemoradiotherapy.

NPC Patients receiving IMRT treatment will receive a dedicated FDG PET/CT and high-sensitivity PET/CT protocol simultaneously 12 weeks after the end of chemoradiotherapy (primary endpoint).

The results of FDG PET/CT and high-sensitivity PET/CT analyzed and compared.

Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients

The results of the two tests were compared to verify the specificity and sensitivity of ultrasensitive PET CT in post treatment NPC

Sun Yat-sen University

Chief Physician

Symptoms and General Pathology

Digestive System Diseases

Recurrence

Carcinoma, Hepatocellular

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

All Drugs and Chemicals

Hematinics

Fluorodeoxyglucose F18

Liver Extracts

Imidacloprid

Milan-out, up-to-7-in, PET negative (≤1.15) HCC patients

Both groups will receive the same advantages on the LT waiting list (SE points)

Liver transplantation

Olivier Detry, MD PhD

Céline Lambrecht

Dirk Ysebaert, MD PhD

Thomas Vanwolleghem, MD PhD

Thierry Gustot, MD PhD

Valerio Lucidi

Hans Van Vlierberge, MD PhD

he, MD PhD

Frederik Berrevoet, MD PhD

Hans Van Vlierberghe, MD PhD

Chris Verslype, MD PhD

Jacques Pirenne, MD PhD

Frederik Nevens, MD PhD

Celine Lambrecht

Jean Delwaide, MD PhD

Ivan Borbath, MD PhD

Ivan Borbath

Geraldine Dahlqvist

Eliano Bonaccorsi

Hepatocellular carcinoma (HCC) is a rising public health concern with few curative options but liver transplantion (LT) in highly selected cases. LT could save many other HCC patients but organ shortage has lead to the necessity of selection of patients with the best survival chances, namely the Milan criteria. Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the third cause of cancer related-death worldwide. HCC incidence is rising in Western countries including Belgium. There are more than 1,000 new HCC diagnoses in Belgium every year, but only 90 to 100 patients suffering from HCC are listed for liver transplantation (LT). In fact, the scarcity of organ donors has forced the development of strict criteria to limit LT to patients who are likely to have excellent outcomes. The universally accepted LT criteria for HCC are the Milan criteria (1 HCC nodule ≤5 cm or 3 nodules ≤3cm) that lead to a low rate of post-LT recurrence (\>80% of disease free recurrence at 5 years). The majority of patients suffering from HCC outside the Milan criteria at the time of diagnosis is not eligible for LT and is therefore limited to palliative care. It is however considered that some of these patients with HCC outside the Milan criteria may benefit from LT with an acceptable risk of recurrence and chances of long-term disease-free survival (DFS). This fact has led to the extension of LT criteria for HCC in some centres in different countries, as for example the University of California San Francisco (UCSF) criteria, the up-to-seven criteria or the Asan criteria.

The Belgian Liver-Intestine Allocation Committee (Be-LIAC) is a section of the Belgian Transplantation Society (BTS) composed of the 6 LT Belgian centres in charge of coordinating deceased LT activity in Belgium with the help of Eurotransplant. Be-LIAC has already built a retrospective HCC database that was successfully used for several scientific studies allowing international presentations and publications. Based on this successful experience, Be-LIAC is keen to continue with this national collaboration to initiate a prospective clinical observational database to better study the results of LT in Belgium and to evaluate potential of extension of LT criteria in HCC patients. Inclusion in this database will not change patient management or the allocation process of the liver grafts in Belgium. This project is financed by a 4-year (2019-2022) grant of the Belgian "Fondation contre le cancer" / "Stichting tegen Kanker".

All adult patients (\> 18 and \< 80 years) suffering from HCC and discussed for potential deceased or living related LT during multidisciplinary oncologic meetings in the 6 Belgian LT centres will be consecutively included in the prospective database after signing an informed consent form. Date of inclusion will be the date of discussion at the first multidisciplinary oncological meeting. All patients who are not contra indicated for LT due to general medical conditions (as presented in the exclusion criteria) or due to HCC staging (evidence of extrahepatic extension or cancerous macroscopic invasion of a liver vein at imaging) will be included in the database. These patients will be either directly listed on the Eurotransplant waiting list if considered within the local LT criteria by the given centre, or potentially listed after successful down-staging or HCC recurrence after a first attempt of curative management (ex: resection, radiofrequency ablation (RFA), ....).

A prospective, secured, anonymized (GDPR compliant), web-based database will be constructed with the help of an experienced company.

For LT listing, diagnosis of HCC will be based on international recommendations and Eurotransplant rules, either on biopsy or on imaging (AFP \>400 ng/mL and 1 positive result with hypervascularisation on CT and/or MRI), or AFP \< 400ng/mL and 2 positive results with CT and MRI). Hepatic lesions of \<1cm will not be considered for preoperative radiologic staging. All of the relevant liver images will be stored in a secured (GDPR compliant) web-based server and will be reviewed by a multicentre panel of expert radiologists in order to confirm the radiologic staging according to Milan and up-to-seven criteria.

Registration of HCC patients on the Eurotransplant waiting list will not be modified. Transplant candidates will be registered on the LT waiting list according to Eurotransplant and Be-LIAC allocation rules:

* 1 HCC nodule \> 2cm: labMELD score;
* HCC within the Milan criteria: (1 HCC nodule ≤ 5 cm or 3 nodules ≤ 3cm) exceptional standard exception (SE) MELD points;
* HCC outside the Milan criteria but successfully down-staged to inside Milan criteria: exceptional SE MELD points;
* HCC outside Milan criteria, within up-to-7 criteria, PET negative (≤ 1.15): exceptional SE MELD points;
* HCC outside Milan criteria, within up-to-7 criteria, PET positive (\> 1.15) or outside up-to-7 criteria: labMELD score.

Nodules ≤ 1 cm will be taken into account.

After transplantation, patients will undergo regular life-long immunosuppression according to the centre preferences. In the context of a malignant disease, the use of mTOR inhibitors will be encouraged but not mandatory, as suggested in the recent literature. The type of immunosuppression (induction therapy, calcineurin inhibitors, mTOR inhibitors, antimetabolites, steroids) will be recorded in the database. No adjuvant therapy will be performed in patients without evidence of recurrence.

Posttransplant tumour surveillance program will be standard for LT recipients with HCC and will consist in at least whole body CT every 6 months during the first 2 years, and AFP level measurement every 3-6 months during the entire follow-up period in patients with elevated pretransplant AFP. The date and site of recurrence will be recorded as well as survival data. Management of recurrence will be performed according to the centre policy and recorded in the database. As for other solid organ transplant recipients, all LT patients included in this study will be indefinitely followed by local transplant centres, allowing mid- and long-term (10 years) follow-ups.

Recorded data

* Patient's characteristics: Patient code generated by Eonix, internal patient code at the transplant center, Eurotransplant listing with the number and date of registration, ET listing criteria, country of residence, ethnicity, age, gender, blood group, BMI, viral status, cause of cirrhosis, diabetic status, smoking status, cancer status, history of liver and/or obesity surgery, cause of chronic liver disease, ascites and encephalopathy grade and Milan status at the Eurotransplant listing. If an HCC would have been treated in the past, more information will be required.
* HCC Data: - CT scan with the date, number of nodules and their sizes as well as their classification (TNM grade according to UICC 2018);

  - MRI with the date, the numbers of nodules and their size and their classification (TNM grade); - tumour biopsy with date and characteristics (differentiation, invasion) if performed; - FDG-PET / CT with the characteristics SUV max (\> 1.15) or SUV max (≤1.15); Medium SUV; the ratio between max SUV of the tumour with max SUV of a "normal" liver .
* Pre-transplant visits every 3 months: date, hemoglobin, platelets, white cells, neutrophils, lymphocytes, monocytes, international normalized ratio (INR), total bilirubin, creatinin, C-reactive protein (CRP), AFP, CA19-9, albumin and natrium. Lab-MELD score, encephalopathy and ascites grade, allowing determining Child Pugh score, CT scan/MRI every 3 to 4 months to monitor the nodules and their evolution. In addition, in some patients, blood samples will be stored in the biobank center. Additional informed consent will need to be signed by the patient to allow to retain vital biological data for future research. Standard neo-adjuvant HCC management (also called "bridge-to-transplant") will be performed according to the local multidisciplinary team decision, including resection, RFA, chemoembolization, radioembolization, Sorafenib, stereotaxic radiotherapy or no therapy. These informations will be included in the database. While on the LT waiting list, patients will be followed by CT/MRI and AFP level every 3 to 4 months, allowing the evaluation of the evolution of the tumour size and the ΔAFP. Response to neo-adjuvant therapy will be determined according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST): complete-response (CR), partial-response (PR), stable-disease (SD) and progressive-disease (PD).
* Liver transplant data: Recipients pretransplant last lab values: hemoglobin, platelets, white cells, neutrophils, lymphocytes, monocytes, INR, total bilirubin, creatinine, CRP, AFP, albumin, natrium, encephalopathy and ascites grade, waiting time before transplant, lab and exceptional MELD score at LT, Eurotransplant donor number, age of donor, type of donor, type of graft, graft origin, donor total bilirubin, ET donor risk index (ET-DRI), graft biopsy, time of ischemia, blood transfusion during surgery and after, need renal support, transaminase peak, total bilirubin at day 7, number of days in ICU, number of hospitalisation days.
* Pathology of explanted livers. Number of nodules and their sizes as well as their classification (TNM grade according to UICC 2018). These samples will be stored in the center's biobank to allow for further analyses needed for research in liver oncology. A consent must be signed by the patient.
* Follow up visits after LT: 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months, 60 months, 66 months, 72 months, 78 months, 84 months, 90 months, 96 months, 102 months, 108 months, 114 months, 120 months:

Biology at follow up: AFP, tacrolimus level, everolimus level. Recorded informations: immunosuppression, graft survival, cause of transplant failure, the date of retransplantation, cause of patient death, recurrence of HCC and its location and planned treatment. A body CT will be performed at 6 months, 12 months, 18 months, 24 months, 32 months, 44 months and 60 months.

The HCC liver explant stored in the local biobank of the transplant center.

Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates

Extension of Liver Transplantation Opportunity to Patients Suffering From Milan-out, Up-to-7-in, Hepatocellular Carcinoma: a Prospective Belgian Study of the Value of Negative 18FDG PET/CT

Intention-to-treat (at LT waiting list registration) and post LT disease-free (DFS), recurrence-free (RFS) and overall survivals (OS)

Comparison of FDG-PET/CT to the other prognostic HCC prognostic factors, as the radiologic and pathologic Milan criteria, the UCSF criteria, the up-to-seven criteria, the Asan criteria and the AFP model

Evaluation of the value of positive or negative FDG-PET/CT in Milan-in HCC patients listed for LT and the impact on outcome in these patients

University Hospital, Ghent

Free University of Brussels

University Hospital, Antwerp

Universitaire Ziekenhuizen KU Leuven

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

University of Liege

Associate professor, Surgical head of the liver transplantation program

Ho Yun Lee, Dr

The purpose of this study is to evaluate relationships between multiparametric imaging biomarkers and genetic analysis in NSCLC patients.

To evaluate relationships between multiparametric imaging biomarkers(CT, PET/CT, MRI) and genetic analysis in NSCLC patients

Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers

Prognostic stratification will be evaluated using following parameters:

1. Quantitative and qualitative parameters from CT, PET, MRI
2. Genomic data of lung cancer samples

We will evaluate if certain relationship exists between changes in multiparametric imaging markers from CT, PET, MRI and genomic informations of NSCLC.

following parameters exracted from whole lung will be evaluated: Quantitative parameters related to pulmonary function from CT, PET, MRI 2. Prediction of longitudinal changes of pulmonary function after the lung resection

Samsung Medical Center

Assistant Professor

Uterine Cervical Neoplasms

Uterine Neoplasms

Genital Neoplasms, Female

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Radiotherapy

Amnon Amit, MD

Cervical Cancer is staged clinically, not surgically. Patients in whom an extensive disease is identified are not usually eligible for surgery. PET-CT is used to support staging. However, some patients received surgery after staging and subsequently require radio/chemotherapy due to findings on operation.

This study will attempt to find a correlation between SUV-Max on PET-CT and subsequent outcomes i.e. need for adjuvant therapy.

SUV Max as Predictor of Outcome in Cervical Cancer

A Study to Evaluate the Value of SUV-Max in PET-FDG in Predicting Outcome of Surgery Vis a Vis Need for Radiotherapy

Rambam Health Care Campus

Dr. Amit Amnon, director, gynecologic oncology unit

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

measurement of surgical margins during lumpectomy

Menekse Goker

Examination of the feasibility of intra-operative pet CT to detect surgical margins in breast conservative surgery to prevent re-excision.

Intra-operative PET-CT: a Novel Approach to Determine Excision Margins in Lumpectomy Breast Cancer.

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Neuroepithelioma

Cardiotonic Agents

Fluorides

Dihydroxyphenylalanine

Dopamine

Dopamine Agents

Neurotransmitter Agents

18F-DOPA PET imaging will be used to guide radiotherapy treatment volumes and patients will be followed post-treatment to analyze response and patterns of failure

5 millicuries ± 10%; Intravenous injection; 1 time

Fluorine-18-L-dihydroxyphenylalanine

Nadia N Laack, MD

Debra Brinkmann, PhD

Deanna Pafundi, PhD

For most brain tumors, radiation treatment is guided by a Magnetic Resonance Imaging (MRI) scan. In this study, information from a special scan, called a Positron Emission Tomography/ Computed Tomography (PET/CT) scan using an amino acid called Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) will also be used. This type of scan has shown promise in being able to better distinguish tumor from normal brain tissue and may help to more accurately plan radiation treatment. This type of scan can also assist the radiation oncologist in identifying the most aggressive regions of the tumor. The goal of this study is to compare the 18F-DOPA PET/CT scan with the MRI scan for identifying where the disease is that needs to be treated with radiation.

A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas

A Pilot Study Evaluating the Utility of 18F-DOPA PET for Radiotherapy Treatment Planning of Malignant Glioma Patients

The primary endpoint for this pilot study will be to compare radiotherapy treatment volumes defined by conventional MR-only with treatment volumes defined with both 18F-DOPA PET and conventional MR information

For patients who have advanced MRI scans performed as part of standard clinical care, advanced MRI volumes will be compared with conventional MRI volumes as well as 18F-DOPA PET volumes

For patients who progress radiographically within the observation period of this study will compare concordance of recurrence locations with pre-treatment 18F-DOPA PET uptake

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer	NCT04053101	Muscle Invasive...	PET CT	18 Years -	Institut Bergonié
PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer	NCT03146117	PET CT		18 Years -	Medical University of South Carolina
Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients	NCT04394091	Nasopharyngeal ...	ultrasensitive ...	18 Years - 70 Years	Sun Yat-sen University
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer	NCT04053101	Muscle Invasive...	PET CT	18 Years -	Institut Bergonié
Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates	NCT05276037	Hepatocellular ...	Liver transplan...	18 Years - 80 Years	University of Liege
Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers	NCT01585545	Lung Cancer		20 Years -	Samsung Medical Center
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer	NCT04053101	Muscle Invasive...	PET CT	18 Years -	Institut Bergonié
SUV Max as Predictor of Outcome in Cervical Cancer	NCT01262144	Cervical Cancer	Radiotherapy	18 Years - 80 Years	Rambam Health Care Campus
SUV Max as Predictor of Outcome in Cervical Cancer	NCT01262144	Cervical Cancer	Radiotherapy	18 Years - 80 Years	Rambam Health Care Campus
Intra-operative PET-CT: a Novel Approach to Determine Excision Margins in Lumpectomy Breast Cancer.	NCT04343079	Breast Cancer F... Breast Neoplasm...	PET CT	18 Years - 85 Years	University Hospital, Ghent
A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas	NCT02104310	Malignant Gliom...	Fluorine-18-L-d...	7 Years -	Mayo Clinic

Spots Global Cancer Trial Database for pet ct

Every month we try and update this database with for pet ct cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for pet ct

Every month we try and update this database with for pet ct cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for pet ct cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.